LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Spatial Landscape of Lung Pathology Investigated During COVID-19 Progression

By LabMedica International staff writers
Posted on 13 Apr 2021
Print article
Image: The Hyperion Imaging System brings proven CyTOF technology together with imaging capability to empower simultaneous interrogation of four to 37 protein markers using Imaging Mass Cytometry (Photo courtesy of Fluidigm)
Image: The Hyperion Imaging System brings proven CyTOF technology together with imaging capability to empower simultaneous interrogation of four to 37 protein markers using Imaging Mass Cytometry (Photo courtesy of Fluidigm)
Early histopathological changes of viral pneumonias are rarely observed because histopathological examination is not necessary for diagnosis, but late stage changes in viral pneumonias are well defined, most commonly in autopsy series.

Since the outbreak of the COVID-19 pandemic, much has been learned regarding its clinical course, prognostic inflammatory markers, disease complications, and mechanical ventilation strategy. Clinically, three stages have been identified based on viral infection, pulmonary involvement with inflammation, and fibrosis.

Medical Scientists at Weill Cornell Medicine (New York, NY, USA) and their colleagues used high parameter imaging mass cytometry to measure the expression level of 36 proteins at single-cell resolution, allowing them to characterize the pathophysiology and immune response in the lungs of 10 patients who died from COVID-19. They investigated at single cell resolution, the cellular composition and spatial architecture of human acute lung injury including SARS-CoV-2. The team also looked at samples from patients who died with acute respiratory distress syndrome from influenza (two patients), bacterial infection (four patients), and bacterial pneumonia (three patients), along with post-mortem lung tissue from four otherwise healthy individuals.

The panel included phenotypic markers of endothelial, epithelial, mesenchymal, and immune cells, functional markers (activation, inflammation and cell death), and an antibody specific to the spike protein of SARS-CoV-2. They used immunohistochemistry and targeted spatial transcriptomic measurements to validate their imaging mass cytometry findings from the Hyperion Imaging System (Fluidigm, South San Francisco, CA, USA).

The scientists reported that the spatially resolved, single-cell data unravels the disordered structure of the infected and injured lung alongside the distribution of extensive immune infiltration. Neutrophil and macrophage infiltration are hallmarks of bacterial pneumonia and COVID-19, respectively. They provided evidence that SARS-CoV-2 infects predominantly alveolar epithelial cells and induces a localized hyper-inflammatory cell state associated with lung damage. They observed increased macrophage extravasation, mesenchymal cells, and fibroblasts abundance concomitant with increased proximity between these cell types as the disease progresses, possibly as an attempt to repair the damaged lung tissue.

Robert Schwartz, MD, PhD, an associate professor of medicine and senior author on the study, said, “In contrast to other lung injury or disease processed, there is widespread tissue damage in late COVID-19 marked by the high amounts of pro-apoptotic cleaved caspase 3 and the off-target deposition of activated complement C5b-C9 attack complex in epithelial cells.”

The authors concluded that this spatial single-cell landscape enabled the pathophysiological characterization of the human lung from its macroscopic presentation to the single-cell, providing an important basis for the understanding of COVID-19, and lung pathology in general. The study was published on March 29, 2021 in the journal Nature.

Related Links:
Weill Cornell Medicine
Fluidigm


Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.